Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905825 · ClinicalTrials.gov registry record · Phase 3
Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics
A Phase 3 study, sponsored by Meridian Bioscience.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT02905825: Completed Phase 3 study, sponsored by Meridian Bioscience.
NCT02905825 is a Phase 3 study that has completed, run by Meridian Bioscience. The registered enrollment target is 54 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02905825, a Phase 3 study, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
Clinical Study to Confirm Safety and Accuracy in Detection of H. pylori with 13C-Urea Breath Test using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population
Primary Outcome
Number of participants with reported adverse events after performing urea breath test
Interventions
- DEVICE BreathID® Hp System
- DRUG BreathID® Hp Lab System
- DIAGNOSTIC_TEST Stool Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2017-11-05 |
| Phase | Phase 3 |
What the finished NCT02905825 record still lists
NCT02905825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which BreathID® Hp System is the first listed.
NCT02905825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02905825 about?
NCT02905825 is a clinical study titled "Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics". Clinical Study to Confirm Safety and Accuracy in Detection of H. pylori with 13C-Urea Breath Test using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population
What is the current status of trial NCT02905825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2017-05-18. Estimated completion is 2017-11-05.
What interventions are being tested in trial NCT02905825?
The interventions under investigation include: BreathID® Hp System (DEVICE), BreathID® Hp Lab System (DRUG), Stool Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02905825?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02905825's enrollment target sits among peer trials
54 1838th of 2000 higher than 162 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI